Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Moutafi MK, et al. Among authors: ponce aix s. J Immunother Cancer. 2022 Aug;10(8):e004757. doi: 10.1136/jitc-2022-004757. J Immunother Cancer. 2022. PMID: 36002182 Free PMC article.
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, Provencio M, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P. Zugazagoitia J, et al. Among authors: ponce aix s. Lung Cancer. 2019 Aug;134:72-78. doi: 10.1016/j.lungcan.2019.05.032. Epub 2019 May 30. Lung Cancer. 2019. PMID: 31319999
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.
Ramos-Paradas J, Hernández-Prieto S, Lora D, Sanchez E, Rosado A, Caniego-Casas T, Carrizo N, Enguita AB, Muñoz-Jimenez MT, Rodriguez B, Perez-Gonzalez U, Gómez-Sánchez D, Ferrer I, Ponce Aix S, Nuñez Buiza Á, Garrido P, Palacios J, Lopez-Rios F, Garrido-Martin EM, Paz-Ares L. Ramos-Paradas J, et al. Among authors: ponce aix s. J Immunother Cancer. 2021 May;9(5):e001904. doi: 10.1136/jitc-2020-001904. J Immunother Cancer. 2021. PMID: 33963008 Free PMC article.
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S. Zugazagoitia J, et al. Among authors: ponce aix s. Clin Lung Cancer. 2018 Jan;19(1):65-73.e7. doi: 10.1016/j.cllc.2017.06.008. Epub 2017 Jun 23. Clin Lung Cancer. 2018. PMID: 28780976
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer.
Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, Manzano A. Zugazagoitia J, et al. Among authors: ponce aix s. Eur Respir J. 2018 May 3;51(5):1702431. doi: 10.1183/13993003.02431-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29563169 Free article. No abstract available.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. Levy BP, et al. Among authors: ponce aix s. Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654297 Clinical Trial.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Among authors: ponce aix s. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
48 results